ASSESSMENT OF PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) TREATED WITH OBETICHOLIC ACID (OCA): RESULTS FROM REGENERATE PHASE 3 CLINICAL TRIAL

被引：0

作者：

Younossi, Zobair M. ^{[1
,2
,3
]}

Stepanova, Maria ^{[4
]}

Nader, Fatema ^{[4
]}

Loomba, Rohit ^{[5
]}

Anstee, Quentin M. ^{[6
]}

Ratziu, Vlad ^{[7
]}

Harrison, Stephen A. ^{[8
]}

Sanyal, Arun J. ^{[9
]}

Trotter, James F. ^{[10
]}

Sheikh, Muhammad Y. ^{[11
]}

Montano-Loza, Aldo J. ^{[12
]}

Olveria, Antonio ^{[13
]}

Stinton, Laura M. ^{[14
]}

Sheridan, David A. ^{[15
,16
]}

Vargas, Victor ^{[17
]}

Gluud, Lise L. ^{[18
]}

Safadi, Rifaat ^{[19
]}

Schattenberg, Joern ^{[20
]}

Khalili, Mandana ^{[21
]}

Orr, David W. ^{[22
]}

Peck-Radosavljevic, Markus ^{[23
]}

Allison, Michael E. ^{[24
]}

Cawkwell, Gail ^{[25
]}

Wong, Bruce ^{[25
]}

Bedossa, Pierre ^{[26
]}

Goodman, Zachary D. ^{[1
,27
]}

Rinella, Mary E. ^{[28
]}

机构：

[1] Inova Hlth Syst, Betty & Guy Beatty Ctr Integrated Res, Falls Church, VA USA

[2] Inova Fairfax Hosp, Ctr Liver Dis, Falls Church, VA USA

[3] Inova Fairfax Hosp, Dept Med, Falls Church, VA USA

[4] Ctr Outcomes Res Liver Dis, Washington, DC USA

[5] Univ Calif San Diego, NAFLD Res Ctr, San Diego, CA 92103 USA

[6] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England

[7] AP HP, Paris, France

[8] Univ Oxford, Oxford, England

[9] VCU, Richmond, VA USA

[10] Texas Digest Dis Consultants, Clin Res, Dallas, TX USA

[11] Fresno Clin Res Ctr, Fresno, CA USA

[12] Univ Alberta, Edmonton, AB, Canada

[13] Hosp Univ, Madrid, Spain

[14] Univ Calgary, Med, Calgary, AB, Canada

[15] Plymouth Hosp NHS Trust, Plymouth, Devon, England

[16] Plymouth Univ, Plymouth, Devon, England

[17] Hosp Valle De Hebron, Barcelona, Spain

[18] Copenhagen Univ Hosp Hvidore, Hvidovre, Denmark

[19] Hadassah Hebrew Univ Med Ctr, Hadassah Med Org, Jerusalem, Israel

[20] Univ Med Ctr Mainz, Dept Med, Mainz, Germany

[21] Univ Calif San Francisco, San Francisco, CA 94143 USA

[22] Auckland City Hosp, Auckland, New Zealand

[23] Med Univ Wien, Vienna, Austria

[24] Addenbrookes Hosp, Dept Hepatol, Cambridge, England

[25] Intercept Pharmaceut, New York, NY USA

[26] Hop Beaujon, Clichy, France

[27] Inova Fairfax Hosp, Falls Church, VA USA

[28] Feinberg Sch Med, Chicago, IL USA

来源：

HEPATOLOGY | 2019年 / 70卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

2324

引用

页码：1366A / 1368A

页数：3

共 50 条

[41] Final results from the phase 3 REGENERATE trial evaluating the effects of obeticholic acid in patients with pre-cirrhotic fibrosis due to metabolic dysfunction-associated steatohepatitis
Sanyal, Arun J.
Loomba, Rohit
Anstee, Quentin M.
Ratziu, Vlad
Kowdley, Kris V.
Lawitz, Eric
White, Christopher
Sawhney, Sangeeta
Capozza, Thomas
Leyva, Rina
Younossi, Zobair
Rinella, Mary E.
Abdelmalek, Manal F.
JOURNAL OF HEPATOLOGY, 2024, 80 : S95 - S95
[42] CANAKINUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RECURRENT FEVER SYNDROMES: RESULTS FROM A PHASE 3 TRIAL (CLUSTER)
Lachmann, Helen J.
Lauwerys, Bernard
Miettunen, Paivi
Kallinich, Tilmann
Horneff, Gerd
Brik, Riva
Manna, Rafaelle
Murias, Sara
Savic, Sinisa
Smeets, Serge
De Benedetti, Fabrizio
Simon, Anna
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 207 - 208
[43] Impact of Early Pain Improvement on Patient-reported Outcomes in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial
Bessette, Louis
Joven-Ibanez, Beatriz
Selmi, Carlo
Chen, Naijun
Kato, Koji
Lippe, Ralph
Zueger, Patrick
Patel, Jayeshkumar
Merola, Joseph
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 465 - 468
[44] Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial (vol 394, pg 2184, 2019)
Younossi, Z. M.
Ratziu, V
Loomba, R.
LANCET, 2020, 396 (10247): : 312 - 312
[45] Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib plus fulvestrant: Results from MONALEESA-3
Fasching, P. A.
Esteva, F. J.
Pivot, X.
Nusch, A.
Beck, J. T.
Chan, A.
Pieris-Gunatilaka, A.
Wang, Y.
Lanoue, B.
Chandiwana, D.
Neven, P.
ANNALS OF ONCOLOGY, 2018, 29
[46] The clinical and patient reported outcomes (PROs) profile of patients with non-alcoholic fatty liver disease (NAFLD) from real-world practices varies across the world
Younossi, Zobair
Yilmaz, Yusuf
Yu, Ming-Lung
El Kassas, Mohammed
Castellanos-Fernandez, Marlen
Wong, Vincent Wai-Sun
Isakov, Vasily
Duseja, Ajay Kumar
Mendez-Sanchez, Nahum
Papatheodoridis, George
Chan, Wah-Kheong
George, Jacob
Fan, Jian-Gao
Bugianesi, Elisabetta
Eguchi, Yuichiro
Younes, Ziad H.
Romero Gomez, Manuel
Roberts, Stuart
Gordon, Stuart C.
Hamid, Saeed
Ahmed, Aijaz
Ong, Janus
Alqahtani, Saleh
Lam, Brian
Ziayee, Mariam
Younossi, Issah
Nader, Fatema
Racilla, Andrei
Stepanova, Maria
JOURNAL OF HEPATOLOGY, 2020, 73 : S111 - S111
[47] BARRIERS AND FACILITATORS TO IMPLEMENTING ELECTRONIC PATIENT-REPORTED OUTCOMES (PROS) IN CANCER CLINICAL TRIALS: INTERVIEW RESULTS FROM CLINICAL RESEARCH STAFF AND PATIENTS
Fayanju, O.
Stover, A.
Teal, R.
Rogak, L.
Bennett, A., V
Basch, E. M.
VALUE IN HEALTH, 2019, 22 : S541 - S541
[48] Impact of adalimumab treatment on patient-reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis
Revicki, Dennis A.
Willian, Mary Kaye
Menter, Alan
Gordon, Kenneth B.
Kimball, Alexa B.
Leonardi, Craig L.
Langley, Richard G.
Kimel, Miriam
Okun, Martin
JOURNAL OF DERMATOLOGICAL TREATMENT, 2007, 18 (06) : 341 - 350
[49] Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2
Ostor, Andrew J. K.
Soliman, Ahmed M.
Papp, Kim A.
Padilla, Byron
Wang, Zailong
Eldred, Ann
de Vlam, Kurt
Kivitz, Alan
RMD OPEN, 2022, 8 (02):
[50] Improvements in patient-reported outcomes (PROs) among moderate to severe plaque psoriasis patients treated with brodalumab: Results from AMAGINE-1
Strober, Bruce
Gordon, Kenneth
Augustin, Matthias
Viswanathan, Hema
Klekotka, Paul
Milmont, Cassandra
Kricorian, Gregory
Harrison, David
Pinto, Lionel
Nirula, Ajay
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB256 - AB256

← 1 2 3 4 5 →